Resources

Surveys to vaccine and pharmaceutical regulators and manufacturers on endotoxin testing methodsEndotoxin testing is essential for ensuring the safety of injectable pharmaceutical products by detecting potentially harmful bacterial toxins.Traditional gold standard method, the Limulus Amebocyte Lysate (LAL) test, utilizes horseshoe crab blood for endotoxin detection. However, use of horseshoe crab blood led to the decline in horseshoe crab population. It now poses a significant threat to the sustainability of LAL test, impacting the medical field by potentially jeopardizing the safety of pharmaceutical products and posing a significant threat to public health. Advancements in technology have introduced alternatives, notably the recombinant Factor C (rFC) assay, which offers a sustainable and ethical alternative by eliminating the need for horseshoe crab blood.This survey aims to review current endotoxin testing methods and assess the potential for the rFC method to be adopted by manufacturers in Low- and Middle-Income Countries (LMICs).By evaluating the benefits and challenges of rFC technology, this survey seeks to provide valuable insights into how LMIC manufacturers, regulators and stakeholders might navigate the transition to this innovative method, enhancing their testing capabilities while addressing global sustainability and ethical considerations.

"Uniting forces for MNCH advocacy impact: The game changers," the third in our Africa regional MNCH advocacy dialogues series, was held on September 26, 2024.It featured a moderated discussion with panelists from PATH, World Health Organization, Kakamega MNCH Alliance, and the Centre for Reproductive Health and Education. The resources below include the presentation delivered by the panelists and recordings of the webinar in both English and French.

Drawing on PATH’s global expertise working in primary health care (PHC) for more than 40 years, as well as deep engagement in Kenya, where PATH has supported the government for more than 30 years, PATH regularly serves as a technical partner to the Kenyan government on PHC policy adoption and implementation at both the national and subnational levels. This report highlights examples as well as priorities for future work.

This fact sheet provides an overview of PATH's Center for Vaccine Innovation and Access (CVIA), which works in partnership to develop and deliver lifesaving vaccines to women, children, and communities around the globe. It highlights the critical role that CVIA has had in some of immunization’s greatest successes, saving countless lives and improving health for hundreds of millions around the world. It also provides information about CVIA's broad range of expertise and capabilities.

Neonatal mortality is a critical challenge in underserved areas like Dharni, Maharashtra, where limited access to healthcare and tough terrain hinder timely medical intervention. To address this, PATH, in collaboration with AIIMS Nagpur, introduced a tele-SNCU hub-and-spoke model, leveraging telemedicine to provide real-time consultations and remote monitoring for newborns. This project brief highlights the implementation of this tele-SNCU model, which has significantly reduced neonatal deaths and referrals, enhancing care quality and contributing to progress toward SDG targets.